ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Grand Jury To Consider Charges Against N.M. Community Based Cancer Program Staff Members

January 4, 1980

DRCCA Board Okays Four Concepts, Rejects One, Tables Two Others

May 27, 1983

Institute of Medicine Elects 80 New Members

October 24, 2014

NCI Cooperative Group, Cancer Center Trials Listed

February 29, 2008

ASCO Honors Holland, Koop, Monaco With Special Awards

June 11, 1993

FDA Considering Ways To Improve Process Of Secondary Approvals Of Cancer Drugs

November 1, 1991